Meningitis B Vaccination

The Meningitis B vaccine is recommended in many countries worldwide, particularly for infants, adolescents, and young adults who are at increased risk of Meningitis B. Some of the countries where the Meningitis B vaccine is commonly recommended include:

• United States

• United Kingdom

• Canada

• Australia

• European countries

• Chile

• Argentina

• Brazil

• New Zealand

These countries typically include the Meningitis B vaccine as part of routine childhood immunisation schedules and may also recommend vaccination for other high-risk groups, such as college students and military personnel.

Infants
The Meningitis B vaccine is often recommended as part of routine childhood immunisation schedules, with doses administered starting at 2 months of age, followed by booster doses during infancy and early childhood.

Adolescents or College Students
Adolescents and college students living in close quarters, such as dormitories or military barracks, are at higher risk of Meningitis B outbreaks, making vaccination particularly important in these populations.

Plan to Travel to High-Risk Areas
If you're traveling to regions where Meningitis B is endemic or experiencing outbreaks, vaccination is recommended to reduce your risk of infection.

Risk of Meningococcal Disease
Without vaccination, individuals remain susceptible to Meningitis B, which can lead to severe illness, including meningitis and septicemia, with potential long-term complications or death.

Outbreaks in Closed Settings
Adolescents and college students living in close quarters are at higher risk of Meningitis B outbreaks, which can spread rapidly within these communities, leading to clusters of cases and potential outbreaks.

Limited Treatment Options
Meningococcal disease can progress rapidly and require prompt medical intervention. Prevention through vaccination is crucial, as treatment options for severe cases are limited, and outcomes can be devastating.

The Meningitis B vaccine is typically administered as a series of doses:

Primary Vaccination
For infants, the Meningitis B vaccine is usually given in a series of doses starting at 2 months of age, with additional doses administered at 4 months, 6 months, and 12-23 months of age, depending on the specific vaccine used.

Booster Doses
Booster doses may be recommended for adolescents and young adults, particularly those living in high-risk settings or travelling to endemic areas, to ensure continued protection against Meningitis B.